QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-neutral-on-panbela-therapeutics

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

 hc-wainwright--co-reiterates-neutral-on-panbela-therapeutics

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (OTC:PBLA) with a Neutral.

 hc-wainwright--co-downgrades-panbela-therapeutics-to-neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Panbela Therapeutics (OTC:PBLA) from Buy to Neutral.

 panbela-therapeutics-q1-2024-gaap-eps-228-misses-148-estimate

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate o...

 hc-wainwright--co-maintains-buy-on-panbela-therapeutics-lowers-price-target-to-5

HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price t...

 roth-mkm-maintains-buy-on-panbela-therapeutics-maintains-25-price-target

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (OTC:PBLA) with a Buy and maintains $25 price target.

 panbela-therapeutics-q4-2023-gaap-eps-6590-misses-2434-estimate

Panbela Therapeutics (NASDAQ:PBLA) reported quarterly losses of $(65.90) per share which missed the analyst consensus estimate ...

 top-4-health-care-stocks-that-are-preparing-to-pump-this-month

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

 panbela-regains-nasdaq-compliance
Panbela Regains Nasdaq Compliance
02/15/2024 13:05:07

 roth-mkm-maintains-buy-on-panbela-therapeutics-adjusts-price-target-to-25

Roth MKM analyst Jonathan Aschoff maintains Panbela Therapeutics (NASDAQ:PBLA) with a Buy, adjusts target to $25 from $500.

 whats-going-on-with-panbela-therapeutics-stock-today

Panbela Therapeutics announced acceptance of SBP-101 abstract for presentation and disclosed details of a public offering, expe...

 panbela-therapeutics-announced-abstract-for-sbp-101-accepted-for-poster-presentation-at-american-association-for-cancer-research

Poster PresentationTitle:  Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovari...

 crude-oil-down-over-1-science-37-holdings-shares-spike-higher

U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. Th...

 why-panbela-therapeutics-shares-are-trading-lower-by-65-here-are-other-stocks-moving-in-mondays-mid-day-session

Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of...

 dow-edges-lower-cardlytics-shares-jump

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 20 points on Monday. The Dow traded ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION